Flolan®

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	9

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

trials per page:

Showing 1 to 9 of 9 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01462565 (ClinicalTrials.gov)	November 1, 2011	13/10/2011	Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hyperten ...	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	Hypertension, Pulmonary	Drug: current marketed FLOLAN (epoprostenol sodium);Drug: new thermo stable formulation of epoproste ...	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	16	Phase 4	United States;Canada;Netherlands
2	EUCTR2010-018322-40-NL (EUCTR)	11/07/2011	19/07/2011	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	Netherlands;Belgium;France;Spain;Italy
3	EUCTR2010-018322-40-ES (EUCTR)	17/06/2011	03/11/2011	Estudio de investigación clínica para evaluar la seguridad de cambiar el Flolan por un nuevo fármaco ...	Estudio de fase 3b multicéntrico, de una única rama, abierto para evaluar los efectos de cambiar de ...	Hipertensión Arterial Pulmonar (HAP) MedDRA version: 14.0;Level: PT;Classification code 10064911;Ter ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	Actelion Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	France;Canada;Belgium;Spain;Netherlands;Italy
4	NCT01431716 (ClinicalTrials.gov)	March 2011	7/9/2011	Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension	Drug: EFI/ACT-385781A	Actelion	NULL	Completed	18 Years	N/A	All	42	Phase 3	Belgium;Canada;France;Italy;Netherlands;Spain
5	EUCTR2010-018322-40-BE (EUCTR)	02/07/2010	07/04/2010	A clinical research study to evaluate the safety of changing from Flolan to a new drug called Epopro ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 3	France;Canada;Spain;Belgium;Netherlands;Italy
6	EUCTR2010-018322-40-FR (EUCTR)	20/05/2010	29/03/2010	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ...	Trade Name: Epoprostenol-Actelion Product Name: Epoprostenol-Actelion Product Code: ACT-385781A INN or ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 3	France;Spain;Belgium;Netherlands;Italy
7	NCT01105117 (ClinicalTrials.gov)	May 2010	15/4/2010	Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401	An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A ...	Pulmonary Arterial Hypertension	Drug: ACT-385781A (Actelion Epoprostenol);Drug: Flolan®	Actelion	NULL	Completed	18 Years	65 Years	All	2	Phase 4	United States
8	NCT01105091 (ClinicalTrials.gov)	March 2010	15/4/2010	Epoprostenol for Injection in Pulmonary Arterial Hypertension	A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokineti ...	Pulmonary Arterial Hypertension	Drug: ACT-385781A (Actelion Epoprostenol);Drug: Flolan®	Actelion	NULL	Completed	18 Years	65 Years	All	30	Phase 4	United States
9	NCT00058929 (ClinicalTrials.gov)	October 2002	14/4/2003	A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension	A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutane ...	Pulmonary Arterial Hypertension;Pulmonary Hypertension	Drug: treprostinil sodium	United Therapeutics	NULL	Completed	18 Years	75 Years	Both	39	Phase 4	United States

First Previous1Next Last